Bispecific T-cell engager: Difference between revisions
From IDWiki
(Created page with "* Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target * Used in treating some hematologic malignancies Category:Oncology Category:Biologics") |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
|||
* Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target |
* Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target |
||
* Used in treating some hematologic malignancies |
* Used in treating some hematologic malignancies |
||
== Safety == |
|||
=== Adverse Effects === |
|||
* Some of the most serious adverse effects include [[cytokine release syndrome]] and [[immune effector cell-associated neurotoxicity syndrome]] |
|||
** Usually within days of first dose |
|||
* Causes [[hypogammaglobulinemia]] that can last months to years |
|||
* Most patients develop some [[neutropenia]], which can last weeks |
|||
* Infections are common, mostly bacterial and viral and occasionally fungal |
|||
** Bacterial pneumonia is most common |
|||
** COVID-19, with prolonged course |
|||
** EBV and CMV, cases of JCV |
|||
=== Screening === |
|||
* Consider baseline HIV, EBV, CMV, hepatitis B, and hepatitis C serologies |
|||
=== Antimicrobial Prophylaxis === |
|||
* Unclear role for antibiotics and antifungals, in general |
|||
* Likely [[PJP]] and [[VZV]] prophylaxis for duration of treatment |
|||
[[Category:Oncology]] |
[[Category:Oncology]] |
||
Latest revision as of 03:16, 26 March 2024
Background
- Recombinant proteins that bind to two different antigens, one of which activates T cells and the other binds a cancer target
- Used in treating some hematologic malignancies
Safety
Adverse Effects
- Some of the most serious adverse effects include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome
- Usually within days of first dose
- Causes hypogammaglobulinemia that can last months to years
- Most patients develop some neutropenia, which can last weeks
- Infections are common, mostly bacterial and viral and occasionally fungal
- Bacterial pneumonia is most common
- COVID-19, with prolonged course
- EBV and CMV, cases of JCV
Screening
- Consider baseline HIV, EBV, CMV, hepatitis B, and hepatitis C serologies
